Establishment of enzyme-linked immunosorbent assays for thymidylate synthase and dihydropyriminide dehydrogenase in cancer tissues

Oncology Reports

Volumn 11, Issue 5, 2004, Pages 973-979

  Kurebayashi, Junichi ^a   Yamamoto, Yutaka ^a   Udagawa, Kiyoshi ^a   Okubo, Sumiko ^a   Fukushima, Masakazu ^b   Sonoo, Hiroshi ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Breast cancer; Dihydropyrimidine dehydrogenase; ELISA; Thymidilate synthase

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; THYMIDYLATE SYNTHASE;

ARTICLE; BREAST TUMOR; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYMOLOGY; GENE EXPRESSION REGULATION; HUMAN; IMMUNOLOGY; METABOLISM; METHODOLOGY; STANDARD;

BREAST NEOPLASMS; DIHYDROURACIL DEHYDROGENASE (NADP); ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; REFERENCE STANDARDS; THYMIDYLATE SYNTHASE;

EID: 16544362735     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.11.5.973     Document Type: Article

References (56)

1. Aschele C, Lonardi S and Monfardini S: Thymidylate synthase expression as a predictor of clinical response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer. Cancer Treat Rev 28: 27-47, 2002. (Pubitemid 34679207)
2. Diasio RB: Clinical implications of dihydropyrimidine dehydrogenase on 5-FU pharmacology. Oncology 15 (Suppl. 2): 21-26, 2001.
3. Johnston PG, Drake JC, Trepel J and Allegra CJ: Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res 52: 4306-4312, 1992.
4. Beck A, Etienne MC, Cheradame S, Fischel JL, Formento P, Renee N and Milano G: A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer 30A: 1517-1522, 1994. (Pubitemid 24343014)
5. Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolmark N, Drake JC, Chabner BA and Allegra CJ: The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 12: 2640-2647, 1994. (Pubitemid 24379651)
6. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV and Leichman L: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55: 1407-1412, 1995.
7. Lenz HJ, Leichman CG, Danenberg KD, Danenberg PV, Groshen S, Cohen H, Laine L, Crookes P, Silberman H, Baranda J, Garcia Y, Li J and Leichman L: Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 14: 176-182, 1996. (Pubitemid 26020011)
8. Pestalozzi BC, Peterson HF, Gelber RD, Goldhirsch A, Gusterson BA, Trihia H, Lindtner J, Cortes-Funes H, Simmoncini E, Byrne MJ, Golouh R, Rudenstam CM, Castiglione-Gertsch M, Allegra CJ and Johnston PG: Prognostic importance of thymidylate synthase expression in early breast cancer. J Clin Oncol 15: 1923-1931, 1997. (Pubitemid 27209522)
9. Leichman CG, Lenz HJ, Leichman L, Danenberg K, Baranda J, Groshen S, Boswell W, Metzger R, Tan M and Danenberg PV: Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 15: 3223-3229, 1997. (Pubitemid 27419335)
10. Lenz HJ, Hayashi K, Salonga D, Danenberg KD, Danenberg PV, Metzger R, Banerjee D, Bertino JR, Groshen S, Leichman LP and Leichman CG: p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin Cancer Res 4: 1243-1250, 1998. (Pubitemid 28213336)
11. Kuniyasu T, Nakamura T, Tabuchi Y and Kuroda Y: Immunohistochemical evaluation of thymidylate synthase in gastric carcinoma using a new polyclonal antibody: the clinical role of thymidylate synthase as a prognostic indicator and its therapeutic usefulness. Cancer 83: 1300-1306, 1998. (Pubitemid 28460079)
12. Van Triest B, Pinedo HM, van Hensbergen Y, Smid K, Telleman F, Schoenmakers PS, van der Wilt CL, van Laar JA, Noordhuis P, Jansen G and Peters GJ: Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 non-selected colon cancer cell lines. Clin Cancer Res 5: 643-654, 1999. (Pubitemid 29131976)
13. Aschele C, Debernardis D, Casazza S, Antonelli G, Tunesi G, Baldo C, Lionetto R, Maley F and Sobrero A: Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J Clin Oncol 17: 1760-1770, 1999. (Pubitemid 29269245)
14. Nishimura R, Nagao K, Miyayama H, Matsuda M, Baba K, Matsuoka Y, Yamashita H, Fukuda M, Higuchi A, Satoh A, Mizumoto T and Hamamoto R: Thymidylate synthase levels as a therapeutic and prognostic predictor in breast cancer. Anticancer Res 19: 5621-5626, 1999. (Pubitemid 30093339)
15. Johnston PG, Mick R, Recant W, Behan KA, Dolan ME, Ratain MJ, Beckmann E, Weichselbaum RR, Allegra CJ and Vokes EE: Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer. J Natl Cancer Inst 89: 308-313, 1997. (Pubitemid 27085893)
16. Mizutani Y, Wada H, Ogawa O, Yoshida O, Fukushima M, Nonomura N and Miki T: Prognostic significance of thymidylate synthase activity in bladder carcinoma. Cancer 92: 510-518, 2001. (Pubitemid 32735185)
17. Wang W, Marsh S, Cassidy J and McLeod HL: Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors. Cancer Res 61: 5505-5510, 2001. (Pubitemid 32694934)
18. Fujiwara H, Terashima M, Irinoda T, Takagane A, Abe K, Kashiwaba M, Oyama K, Takahashi M, Maesawa C, Saito K, Takechi T and Fukushima M: Quantitative measurement of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level in gastric cancer by real-time RT-PCR. Jpn J Cancer Res 93: 1342-1350, 2002. (Pubitemid 36104874)
19. Etienne MC, Chazal M, Laurent-Puig P, Magne N, Rosty C, Formento JL, Francoual M, Formento P, Renee N, Chamorey E, Bourgeon A, Seitz JF, Delpero JR, Letoublon C, Pezet D and Milano G: Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. J Clin Oncol 20: 2832-2843, 2002. (Pubitemid 34651512)
20. Terashima M, Irinoda T, Fujiwara H, Nakaya T, Takagane A, Abe K, Yonezawa H, Oyama K, Inaba T, Saito K, Takechi T and Fukushima M: Roles of thymidylate synthase and dihydropyrimidine dehydrogenase in tumor progression and sensitivity to 5-fluorouracil in human gastric cancer. Anticancer Res 22: 761-768, 2002. (Pubitemid 34475226)
21. Edler D, Glimelius B, Hallstrom M, Jakobsen A, Johnston PG, Magnusson I, Ragnhammar P and Blomgren H: Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol 20: 1721-1728, 2002. (Pubitemid 34273259)
22. Allegra CJ, Paik S, Colangelo LH, Parr AL, Kirsch I, Kim G, Klein P, Johnston PG, Wolmark N and Wieand HS: Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol 21: 241-250, 2003. (Pubitemid 46606152)
23. Takabayashi A, Iwata S, Kawai Y, Kanai M, Taki Y, Takechi T and Fukushima M: Dihydropyrimidine dehydrogenase activity and mRNA expression in advanced gastric cancer analyzed in relation to effectiveness of preoperative 5-fluorouracil-based chemotherapy. Int J Oncol 17: 889-895, 2000.
24. Tanaka-Nozaki M, Onda M, Tanaka N and Kato S: Variations in 5-fluorouracil concentrations of colorectal tissues as compared with dihydropyrimidine dehydrogenase (DPD) enzyme activities and DPD messenger RNA levels. Clin Cancer Res 7: 2783-2787, 2001. (Pubitemid 32911385)
25. Takiguchi N, Koda K, Ooshima H, Oda K, Suzuki H, Ishii R and Miyazaki M: Dihydropyrimidine dehydrogenase-related enzymes predict efficacy and adverse reactions of UFT1 + cisplatin neoadjuvant chemotherapy for gastric cancer. Anticancer Drugs 13: 411-416, 2002. (Pubitemid 34454727)
26. Nakagawa T, Tanaka F, Takata T, Matsuoka K, Miyahara R, Otake Y, Yanagihara K, Fukushimab M and Wada H: Predictive value of dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (Tegafur + Uracil) in patients with p-stage I non-small cell lung cancer. J Surg Oncol 81: 87-92, 2002.
27. Isshi K, Sakuyama T, Gen T, Nakamura Y, Kuroda T, Katuyama T and Maekawa Y: Predicting 5-FU sensitivity using human colorectal cancer specimens: comparison of tumor dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activities with in vitro chemosensitivity to 5-FU. Int J Clin Oncol 7: 335-342, 2002. (Pubitemid 36077315)
28. Copur S, Aiba K, Drake JC, Allegra CJ and Chu E: Thymidilate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil. Biochem Pharmacol 49: 1419-1426, 1995.
29. Otake Y, Tanaka F, Yanagihara K, Hitomi S, Okabe H, Fukushima M and Wada H: Expression of thymidylate synthase in human non-small cell lung cancer. Jpn J Cancer Res 90: 1248-1253, 1999.
30. Lu Z, Zhang R and Diasio RB: Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 53: 5433-5438, 1993. (Pubitemid 23342163)
31. Okabe H, Tsujimoto H and Fukushima M: Preparation of the antibodies against recombinant human thymidylate synthase for the detection of its intratumoral levels and the application to sensitivity-study of 5-fluorouracil. Oncol Rep 4: 685-690, 1997. (Pubitemid 27286971)
32. Lu ZH, Zhang R and Diasio RB: Purification and characterization of dihydropyrimidine dehydrogenase from human liver. J Biol Chem 267: 17102-17109, 1992.
33. Podschun B, Wahler G and Schnackerz KD: Purification and characterization of dihydropyrimidine dehydrogenase from pig liver. Eur J Biochem 185: 219-224, 1989. (Pubitemid 19262341)
34. Spears CP, Shahinian AH and Moran RG: In vivo kinetics of thymidylate synthase inhibition in 5-fluorouracil-sensitive and - resistant murine colon adenocarcinomas. Cancer Res 42: 450-456, 1982. (Pubitemid 12173578)
35. Takechi T, Fujioka A, Matsushita E and Fukushima M: Enhancement of the antitumor activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyrimidine (CDHP) in human tumor cells. Eur J Cancer 38: 1271-1277, 2002. (Pubitemid 34603489)
36. Yunis AA, Arimura GK and Russin DJ: Human pancreatic carcinoma (MIA PaCa-2) in continuous culture: sensitivity to asparaginase. Int J Cancer 19: 218-235, 1977.
37. Adlard JW, Richman SD, Seymour MT and Quirke P: Prediction of the response of colorectal cancer to systemic therapy. Lancet Oncol 3: 75-82, 2002. (Pubitemid 34162977)
38. Bundred NJ: Prognostic and predictive factors in breast cancer. Cancer Treat Rev 27: 137-142, 2001.
39. Rosell R, Taron M and O'Brate A: Predictive molecular markers in non-small cell lung cancer. Curr Opin Oncol 13: 101-109, 2001. (Pubitemid 32242857)
40. Fukushima M, Fujioka A, Uchida J, Nakagawa F and Takechi T: Thymidylate synthase (TS) and ribonucleotide reductase (RNR) may be involved in acquired resistance to 5-fluorouracil (5-FU) in human cancer xenografts in vivo. Eur J Cancer 37: 1681-1687, 2001.
41. Shirota Y, Ichikawa W, Uetake H, Yamada H, Nihei Z and Sugihara K: Intratumoral dihydropyrimidine dehydrogenase messenger RNA level reflects tumor progression in human colorectal cancer. Ann Surg Oncol 9: 599-603, 2002. (Pubitemid 34774423)
42. Shirasaka T, Yamamitsu S, Tsuji A and Taguchi T: Conceptual changes in cancer chemotherapy: from an oral fluoropyrimidine prodrug, UFT, to a novel oral fluoropyrimidine prodrug, S-1, and low-dose FP therapy in Japan. Invest New Drugs 18: 315-329 2000.
43. Schilsky RL and Kindler HL: Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase. Expert Opin Investig Drugs 9: 1635-1649, 2000. (Pubitemid 30433722)
44. Aschele C, Debernardis D, Tunesi G, Maley F and Sobrero A: Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil. Clin Cancer Res 6: 4797-4802, 2000. (Pubitemid 32110422)
45. Foekens JA, Romain S, Look MP, Martin PM and Klijn JG: Thymidine kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy. Cancer Res 61: 1421-1425, 2001. (Pubitemid 34292567)
46. Findlay MP, Cunningham D, Morgan G, Clinton S, Hardcastle A and Aherne GW: Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. Br J Cancer 75: 903-909, 1997. (Pubitemid 27110709)
47. Nozawa H, Tsukui H, Nishida K, Yakumaru K, Nagawa H and Sekikawa T: Dihydropyrimidine dehydrogenase expression in preoperative biopsy and surgically resected specimens of gastric carcinoma. Cancer Chemother Pharmacol 49: 267-273, 2002. (Pubitemid 34253263)
48. Ebuchi M, Sakamoto S, Kudo H, Nagase J and Endo M: Clinicopathological stages and pyrimidine nucleotide synthesis in human mammary carcinomas. Anticancer Res 15: 1481-1484, 1995.
49. Romain S, Spyratos F, Descotes F, Daver A, Rostaing-Puissant B, Bougnoux P, Colonna M, Bolla M and Martin PM: Prognostic of DNA-synthesizing enzyme activities (thymidine kinase and thymidylate synthase) in 908 T1-T2, N0-N1, M0 breast cancers: a retrospective multicenter study. Int J Cancer 87: 860-868, 2000. (Pubitemid 30660567)
50. Romain S, Martin PM, Klijn JG, van Putten WL, Look MP, Guirou O and Foekens JA: DNA-synthesis enzyme activity: a biological tool useful for predicting anti-metabolic drug sensitivity in breast cancer? Int J Cancer 74: 156-161, 1997. (Pubitemid 27234503)
51. Lizard-Nacol S, Genne P, Coudert B, Riedinger JM, Arnal M, Sancy C, Brunet-Lecomte P and Fargeot P: MDR1 and thymidylate synthase (TS) gene expressions in advanced breast cancer: relationships to drug exposure, p53 mutations, and clinical outcome of the patients. Anticancer Res 19: 3575-3581, 1999. (Pubitemid 30000223)
52. Romain S, Bendahl PO, Guirou O, Malmstrom P, Martin PM and Ferno M: DNA-synthesizing enzymes in breast cancer (thymidine kinase, thymidylate synthase and thymidylate kinase): association with flow cytometric S-phase fraction and relative prognostic importance in node-negative premenopausal patients. Int J Cancer 95: 56-61, 2001.
53. Kosaka A, Mori K and Shikata A: Significance of tissue PyNPase, TS, and DPD activities in breast cancer. Gan To Kagaku Ryoho (in Japanese) 29: 1395-1401, 2002.
54. Mori K, Hasegawa M, Nishida M, Toma H, Fukuda M, Kubota T, Nagasue N, Yamana H, Hirakawa-YS Chung K, Ikeda T, Takasaki K, Oka M, Kameyama M, Toi M, Fujii H, Kitamura M, Murai M, Sasaki H, Ozono S, Makuuchi H, Shimada Y, Onishi Y, Aoyagi S, Mizutani K, Ogawa M, Nakao A, Kinoshita H, Tono T, Imamoto H, Nakashima Y and Manabe T: Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues. Int J Oncol 17: 33-38, 2000.
55. Hakamada Y, Arima M, Misaka T, Yasuda D, Matsunaga T, Kusarna M, Aoki T, Sekiguchi N and Koyanagi Y: Significance of thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) activity in breast cancer tissue. Gan To Kagaku Ryoho (in Japanese) 27: 1003-1010, 2000.
56. Hamaji M, Miyazaki S, Nishida Y, Izukura M, Nishijima J, Oka Y, Seshimo I and Ohwari M: A preliminary study on dihydropyrimidine dehydrogenase activity in breast cancer. Gan To Kagaku Ryoho (in Japanese) 27: 1719-1724, 2000. Technology